Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 6;20(5):1141.
doi: 10.3390/ijms20051141.

Proteomics in Psoriasis

Leena Chularojanamontri  1 , Norramon Charoenpipatsin  2 , Narumol Silpa-Archa  3 , Chanisada Wongpraparut  4 , Visith Thongboonkerd  5
Affiliations
Review

Proteomics in Psoriasis

Leena Chularojanamontri et al. Int J Mol Sci. .

Abstract

Psoriasis has been thought to be driven primarily by innate and adaptive immune systems that can be modified by genetic and environmental factors. Complex interplay between inflammatory cytokines and T-cells, especially Th1 and Th17 cells, leads to abnormal cell proliferation and psoriatic skin lesions. Nevertheless, such mechanisms do not entirely represent the pathogenesis of psoriasis. Moreover, earlier and better biomarkers in diagnostics, prognostics, and monitoring therapeutic outcomes of psoriasis are still needed. During the last two decades, proteomics (a systematic analysis of proteins for their identities, quantities, and functions) has been widely employed to psoriatic research. This review summarizes and discusses all of the previous studies that applied various modalities of proteomics technologies to psoriatic skin disease. The data obtained from such studies have led to (i) novel mechanisms and new hypotheses of the disease pathogenesis; (ii) biomarker discovery for diagnostics and prognostics; and (iii) proteome profiling for monitoring treatment efficacy and drug-induced toxicities.

Keywords: biomarker discovery; dermatology; diagnostics; mass spectrometry; prognostics; proteome; psoriatic skin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Sewerin P., Brinks R., Schneider M., Haase I., Vordenbaumen S. Prevalence and incidence of psoriasis and psoriatic arthritis. Ann. Rheum. Dis. 2019;78:286–287. doi: 10.1136/annrheumdis-2018-214065. - DOI - PubMed
    1. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N. Engl. J. Med. 2009;361:496–509. doi: 10.1056/NEJMra0804595. - DOI - PubMed
    1. Mason A.R., Mason J., Cork M., Dooley G., Hancock H. Topical treatments for chronic plaque psoriasis. Cochrane. Database. Syst. Rev. 2013:CD005028. doi: 10.1002/14651858.CD005028.pub3. - DOI - PMC - PubMed
    1. Dauden E., Blasco A.J., Bonanad C., Botella R., Carrascosa J.M., Gonzalez-Parra E., Jodar E., Joven B., Lazaro P., Olveira A., et al. Position statement for the management of comorbidities in psoriasis. J. Eur. Acad. Dermatol. Venereol. 2018;32:2058–2073. doi: 10.1111/jdv.15177. - DOI - PubMed
    1. Zhou F., Zhu Z., Gao J., Yang C., Wen L., Liu L., Zuo X., Zheng X., Shi Y., Zhu C., et al. NFKB1 mediates Th1/Th17 activation in the pathogenesis of psoriasis. Cell Immunol. 2018;331:16–21. doi: 10.1016/j.cellimm.2018.04.016. - DOI - PubMed